Structural basis of Tetherin function

Current HIV Research

Volumn 10, Issue 4, 2012, Pages 298-306

  Weissenhorn, Winfried ^a   Miguet, Nolwenn ^a   Aschman, Nick ^a   Renesto, Patricia ^a   Usami, Yoshiko ^b   Göttlinger, Heinrich G ^b  

^a UNIV GRENOBLE ALPES   (France)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

BST2; Budding; Coiled coil; GPI; HIV 1; SAXS; Tetherin; Vpu

Indexed keywords

MEMBRANE PROTEIN; TETHERIN; UNCLASSIFIED DRUG;

CELL MEMBRANE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRINAE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; VIRUS ENVELOPE; VIRUS RELEASE;

ANTIGENS, CD; CELL LINE; FEMALE; GPI-LINKED PROTEINS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; MALE; MUTATION; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRUS REPLICATION;

EID: 84862622723     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212800792487     Document Type: Review

References (90)

1. Neil, SP Bieniasz. Human immunodeficiency virus, restriction factors, and interferon. J Interferon Cytokine Res 2009; 9(29): 569-80.
2. Sauter, D, A Specht, F Kirchhoff. Tetherin: holding on and letting go. Cell 2010; 141(3): 392-8.
3. Malim, MH. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci 2009; 364(1517): 675-87.
4. Sheehy, AM, N.C Gaddis, J D Choi, MH Malim. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418(6898): 646-50.
5. Sastri, JE Campbell. Recent insights into the mechanism and consequences of TRIM5? retroviral restriction. AIDS Res Hum Retroviruses 2011; 27(3): 231-8.
6. Neil, SJ, T Zang,PD Bieniasz. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451(7177): 425-30.
7. Van Damme, N, D Goff, C Katsura K. et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008; 3(4): 245-52.
8. Le Tortorec, ASJ Neil. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J Virol 2009; 83(22): 11966-78.
9. Zhang, F, SJ Wilson, WC Landford, et al. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 2009; 6(1): 54-67.
10. Jia, B, R Serra-Moreno, W Neidermyer, et al. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 2009; 5(5): e100-0429.
11. Goldstone, DC, V Ennis-Adeniran, JJ Hedden, et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 2011; 480(7377): 379-82.
12. Laguette, N, B Sobhian, N Casartelli, et al. SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474(7353): 654-7.
13. Hrecka, K, C Hao, M Gierszewska, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011; 474(7353): 658-61.
14. Lim, ES, OI Fregoso, CO McCoy, et al. The Ability of Primate Lentiviruses to Degrade the Monocyte Restriction Factor SAMHD1 Preceded the Birth of the Viral Accessory Protein Vpx. Cell Host Microbe 2012; 11(2): 194-204.
15. Sauter, D, M Schindler, A Specht, et al. Tetherin-Driven Adaptation of Vpu and Nef Function and the Evolution of Pandemic and Nonpandemic HIV-1 Strains. Cell Host Microbe 2009; 6(5): 409-421.
16. Martin-Serrano, JSJ Neil. Host factors involved in retroviral budding and release. Nat Rev Microbiol 2010; 9(7): 519-31.
17. Arias, JF, Y Iwabu, K Tokunaga. Structural basis for the antiviral activity of BST-2/tetherin and its viral antagonism. Front Microbiol 2011; 2: 250.
18. Andrew, AK Strebel. The interferon-inducible host factor bone marrow stromal antigen 2/tetherin restricts virion release, but is it actually a viral restriction factor? J Interferon Cytokine Res 2011; 31(1): 137-44.
19. Evans, DT, R Serra-Moreno, RK Singh, JC Guatelli. BST-2/tetherin: a new component of the innate immune response to enveloped viruses. Trends Microbiol 2010; 18(9): 388-96.
20. Douglas, JL, JK Gustin, K Viswanathan, et al. The great escape: viral strategies to counter BST-2/tetherin. PLoS Pathog 2010; 6(5): e1000913.
21. Blasius, AL, E Giurisato, M Cella, et al. Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J Immunol 2006; 177(5): 3260-5.
22. Masuyama, N, T Kuronita, R Tanaka, et al. HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin. J Biol Chem 2009; 284(23): 15927-41.
23. Ohtomo, T, Y Sugamata, Y Ozaki, et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun 1999; 258(3): 583-91.
24. Goto, T, SJ Kennel, M Abe, et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 1994; 84(6): 1922-30.
25. Kawai, S, Y Azuma, E Fujii, et al. Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models. Cancer Sci 2008; 99(12): 2461-6.
26. Neil, SJ, V Sandrin, WI Sundquist, PD Bieniasz. An interferon- alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2007; 2(3): 193-203.
27. Lepelley, A, S Louis, M Sourisseau, et al. Innate Sensing of HIV- Infected Cells. PLoS Pathog 2011; 7(2): e1001284.
28. Liberatore, RA, PD Bieniasz. Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc Natl Acad Sci U S A 2011; 108(44): 18097-101.
29. Cao, W, L Bover, M Cho, et al. Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J Exp Med 2009; 206(7): 1603-14.
30. Cao, WL Bover. Signaling and ligand interaction of ILT7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells. Immunol Rev 2010; 234(1): 163-76.
31. Erikson, E, T Adam, S Schmidt, et al. In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans. Proc Natl Acad Sci U S A 2011; 108(33): 13688-93.
32. Kupzig, S, V Korolchuk, R Rollason, et al. Bst-2/HM1.24 is a raft- associated apical membrane protein with an unusual topology. Traffic 2003; 4(10): 694-709.
33. Dube, M, BB Roy, P Guiot-Guillain, et al. Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J Virol 2009; 83(9): 4574-90.
34. Hauser, H, LA Lopez, SJ Yang, et al. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology 2010; 7: 51.
35. Andrew, AJ, S Kao, K Strebel. C-terminal hydrophobic region in human bone marrow stromal cell antigen 2 (BST-2)/tetherin protein functions as second transmembrane motif. J Biol Chem 2011; 286(46): 39967-81.
36. Fitzpatrick, K, M Skasko, TJ Deerinck, et al. Direct Restriction of Virus Release and Incorporation of the Interferon-Induced Protein BST-2 into HIV-1 Particles. PLoS Pathog 2010; 6(3): e1000701.
37. Lehmann, M, S Rocha, B Mangeat, et al. Quantitative Multicolor Super-Resolution Microscopy Reveals Tetherin HIV-1 Interaction. PLoS Pathog 2011; 7(12): e1002456.
38. Andrew, A, E Miyagi, S Kao, K Strebel. The formation of cysteine- linked dimers of BST-2/tetherin is important for inhibition of HIV- 1 virus release but not for sensitivity to Vpu. Retrovirology 2009; 6(1): 80.
39. Perez-Caballero, D, T Zang, A Ebrahimi, et al. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 2009; 139(3): 499-511.
40. Hinz, A, N Miguet, G Natrajan, et al. Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain. Cell Host Microbe 2010; 7(4): 314-23.
41. McNatt, MW, T Zang, T Hatziioannou, et al. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 2009; 5(2): e1000300.
42. Goffinet, C, I Allespach, S Homann, et al. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 2009; 5(3): 285-97.
43. Sauter, D, S Hue, SJ Petit, et al. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef. Retrovirology 2011; 8(1): 103.
44. Gupta, RK, S Hue, T Schaller, et al. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog 2009; 5(5): e1000443.
45. Iwabu, Y, H Fujita, M Kinomoto, et al. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J Biol Chem 2009; 284(50): 35060-72.
46. Rong, L, J Zhang, J Lu, et al. The transmembrane domain of BST- 2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. J Virol 2009; 83(15): 7536-46.
47. Kobayashi, T, H Ode, T Yoshida, et al. Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility. J Virol 2011; 85(2): 932-45.
48. Vigan, R, SJ Neil. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. J Virol 2010; 84(24): 12958-70.
49. Skasko, M, Y Wang, Y Tian, et al. HIV-1 Vpu Protein Antagonizes Innate Restriction Factor BST-2 via Lipid-embedded Helix-Helix Interactions. J Biol Chem 2012; 287(1): 58-67.
50. Lim, ES, HS Malik, M Emerman. Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses. J Virol 2010; 84(14): 7124-34.
51. Yang, SJ, LA Lopez, H Hauser, et al. Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology 2010; 7: 13.
52. Schindler, M, D Rajan, C Banning, et al. Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue. Retrovirology 2010; 7: 1.
53. Gupta, RK, P Mlcochova, A Pelchen-Matthews, et al. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration Proc Natl Acad Sci USA 2009; 106(49): 20889-94.
54. Serra-Moreno, R, B Jia, M Breed, et al. Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic nef-deleted SIV. Cell Host Microbe 2011; 9(1): 46-57.
55. Bour, S, K Strebel. The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J Virol 1996; 70(12): 8285-300.
56. Abada, P, B Noble, PM Cannon. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J Virol 2005; 79(6): 3627-38.
57. Lau, D, W Kwan, J Guatelli. Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens. J Virol 2011; 85(19): 9834-46.
58. Douglas, JL, K Viswanathan, MN McCarroll, et al. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J Virol 2009; 83(16): 7931-47.
59. Mangeat, B, G Gers-Huber, M Lehmann, et al. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog 2009; 5(9): e1000574.
60. Mitchell, RS, C Katsura, MA Skasko, et al. Vpu antagonizes BST- 2-mediated restriction of HIV-1 release via beta-TrCP and endolysosomal trafficking. PLoS Pathog 2009; 5(5): e1000450.
61. Dube, M, BB Roy, P Guiot-Guillain, et al. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog 2010; 6(4): e1000856.
62. Tervo, HM, S Homann, I Ambiel, et al. Beta-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release. Retrovirology 2011; 8: 9.
63. Janvier, K, A Pelchen-Matthews, JB Renaud, et al. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST- 2/tetherin down-regulation. PLoS Pathog 2011; 7(2): e1001265.
64. Habermann, A, J Krijnse Locker, H Oberwinkler, et al. CD317/Tetherin is enriched in the HIV-1 envelope 1 and downregulated from the plasma membrane upon virus infection. J. Virol 2010; 84(9): 4646-58.
65. Gupta, RK, P Mlcochova, A Pelchen-Matthews, et al. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc Natl Acad Sci U S A 2009; 106(49): 20889-94.
66. Goffinet, C, S Homann, I Ambiel, et al. Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu. J Virol 2010; 84(8): 4089-94.
67. Schmidt, S, JV Fritz, J Bitzegeio, et al. HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction. M Bio 2011; 2(3): e00036-11.
68. Andrew, AJ, E Miyagi, K Strebel. Differential effects of human immunodeficiency virus type 1 Vpu on the stability of BST- 2/tetherin. J Virol 2011; 85(6): 2611-9.
69. Skasko, M, A Tokarev, CC Chen, et al. BST-2 is rapidly down- regulated from the cell surface by the HIV-1 protein Vpu: evidence for a post-ER mechanism of Vpu-action. Virology 2011; 411(1): 65-77.
70. Tokarev, AA, J Munguia, JC Guatelli. Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu. J Virol 2011; 85(1): 51-63.
71. Miyakawa, K, A Ryo, T Murakami, et al. BCA2/Rabring7 promotes tetherin-dependent HIV-1 restriction. PLoS Pathog 2009; 5(12): e100-0700.
72. Swiecki, M, SM Scheaffer, M Allaire, et al. Structural and biophysical analysis of BST-2/tetherin ectodomains reveals an evolutionary conserved design to inhibit virus release. J Biol Chem 2010; 286(4): 2987-97.
73. Blankenfeldt, W, NH Thoma, JS Wray, et al. Crystal structures of human cardiac beta-myosin II S2-Delta provide insight into the functional role of the S2 subfragment. Proc Natl Acad Sci U S A 2006; 103(47): 17713-7.
74. Li, Y, JH Brown, L Reshetnikova, et al. Visualization of an unstable coiled coil from the scallop myosin rod. Nature 2003; 424(6946): 341-345.
75. McNamara, C, AS Zinkernagel, P Macheboeuf, et al. Coiled-coil irregularities and instabilities in group A Streptococcus M1 are required for virulence. Science 2008; 319(5868): 1405-8.
76. Yang, H, J Wang, X Jia, et al. Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proc Natl Acad Sci U S A 2010; 107(43): 18428-32.
77. Schubert, HL, Q Zhai, V Sandrin, et al. Structural and functional studies on the extracellular domain of BST2/tetherin in reduced and oxidized conformations. Proc Natl Acad Sci U S A 2010; 107(42): 17951-6.
78. Hammonds, J, L Ding, H Chu, et al. The Tetherin/BST-2 Coiled- Coil Ectodomain Mediates Plasma Membrane Microdomain Localization and Restriction of Particle Release. J Virol 2011.
79. Garcia, P, Z Ucurum, R Bucher, et al. Molecular insights into the self-assembly mechanism of dystrophia myotonica kinase. Faseb J 2006; 20(8): 1142-51.
80. Rollason, R, V Korolchuk, C Hamilton, et al. Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J Cell Sci 2007; 120(Pt 21): 3850-8.
81. Waheed, AA, EO Freed. The Role of Lipids in Retrovirus Replication. Viruses 2010; 2(5): 1146-80.
82. Casartelli, N, M Sourisseau, J Feldmann, et al. Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog 2010; 6(6): e100-0955.
83. Jolly, C, NJ Booth, SJ Neil. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2- mediated restriction in T cells. J Virol 2010; 84(23): 12185-99.
84. Hammonds, J, JJ Wang, H Yi, P Spearman. Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane. PLoS Pathog 2010; 6(2): e1000749.
85. Miyagi, E, A Andrew, S Kao, et al. Antibody-mediated enhancement of HIV-1 and HIV-2 production from BST-2/tetherin- positive cells. J Virol 2011; 85(22): 11981-94.
86. Neil, SJ, SW Eastman, N Jouvenet, PD Bieniasz. HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog 2006; 2(5): e39.
87. Usami, Y, S Popov, E Popova, et al. The ESCRT pathway and HIV-1 budding. Biochem Soc Trans 2009; 37(Pt 1): 181-4.
88. Dordor, A, E Poudevigne, H Gottlinger, W Weissenhorn. Essential and supporting host cell factors for HIV-1 budding. Future Microbiol 2011; 6(10): 1159-70.
89. Mansouri, M, K Viswanathan, JL Douglas, et al. Molecular mechanism of BST2/Tetherin downregulation by K5/MIR2 of Kaposi's sarcoma herpesvirus. J Virol 2009.
90. Peel, S, P Macheboeuf, N MartinelliW Weissenhorn. Divergent pathways lead to ESCRT-III-catalyzed membrane fission. Trends Biochem Sci 2011; 36(4): 199-210.